Ascletis Pharma Selects Oral Weight-Loss Drug for Further US Studies

MT Newswires Live

02/11

Ascletis Pharma (HKG:1672) said it had selected a once-daily version of the ASC37 oral tablets for further studies in the US, according to a Hong Kong bourse filing Wednesday.

The company plans to seek U.S. regulatory approval to begin human trials of the oral version of the drug to treat obesity.

An investigational new drug application is expected in the second quarter of 2026, the firm said.

According to Ascletis, animal studies showed its medicine was superior to eloralintide and petrelintide.

The company is also advancing a once-monthly subcutaneous version of ASC37.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2610605904"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610605904\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610605904?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-11 09:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610605904","market":"sh","top_or_hot":-1,"title":"Ascletis Pharma Selects Oral Weight-Loss Drug for Further US Studies","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ASCLF\">Ascletis Pharma</a> (HKG:1672) said it had selected a once-daily version of the ASC37 oral tablets for further studies in the US, according to a Hong Kong bourse filing Wednesday.</p><p>The company plans to seek U.S. regulatory approval to begin human trials of the oral version of the drug to treat obesity.</p><p>An investigational new drug application is expected in the second quarter of 2026, the firm said.</p><p>According to Ascletis, animal studies showed its medicine was superior to eloralintide and petrelintide.</p><p>The company is also advancing a once-monthly subcutaneous version of ASC37.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascletis Pharma Selects Oral Weight-Loss Drug for Further US Studies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscletis Pharma Selects Oral Weight-Loss Drug for Further US Studies\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-02-11 09:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ASCLF\">Ascletis Pharma</a> (HKG:1672) said it had selected a once-daily version of the ASC37 oral tablets for further studies in the US, according to a Hong Kong bourse filing Wednesday.</p><p>The company plans to seek U.S. regulatory approval to begin human trials of the oral version of the drug to treat obesity.</p><p>An investigational new drug application is expected in the second quarter of 2026, the firm said.</p><p>According to Ascletis, animal studies showed its medicine was superior to eloralintide and petrelintide.</p><p>The company is also advancing a once-monthly subcutaneous version of ASC37.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01672","symbol_name":"歌禮制藥-B","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2610605904","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610605904","pubTimestamp":1770774544,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Ascletis Pharma  said it had selected a once-daily version of the ASC37 oral tablets for further studies in the US, according to a Hong Kong bourse filing Wednesday.The company plans to seek U.S. regulatory approval to begin human trials of the oral version of the drug to treat obesity.An investigational new drug application is expected in the second quarter of 2026, the firm said.According to Ascletis, animal studies showed its medicine was superior to eloralintide and petrelintide.The company is also advancing a once-monthly subcutaneous version of ASC37.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01672":"歌礼制药-B","BK1161":"生物科技","BK1515":"抗疫概念","BK1574":"生物医药B类股"},"translate_title":"歌礼制药选择口服减肥药在美国进一步研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1.5},"content_text":"Ascletis Pharma (HKG:1672) said it had selected a once-daily version of the ASC37 oral tablets for further studies in the US, according to a Hong Kong bourse filing Wednesday.The company plans to seek U.S. regulatory approval to begin human trials of the oral version of the drug to treat obesity.An investigational new drug application is expected in the second quarter of 2026, the firm said.According to Ascletis, animal studies showed its medicine was superior to eloralintide and petrelintide.The company is also advancing a once-monthly subcutaneous version of ASC37.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}